675
Participants
Start Date
September 29, 2025
Primary Completion Date
November 13, 2026
Study Completion Date
November 13, 2026
Novel Oral Polio Vaccine Type 1 (nOPV1)
nOPV1 containing \>10\^7.0 CCID50 per dose
Novel Oral Polio Vaccine Type 2 (nOPV2)
nOPV2 containing ≥10\^5.0 CCID50 per dose
Placebo (Sterile Water)
Sterile, nonpyrogenic preparation of water which contains no bacteriostat, antimicrobial agent, or added buffer
Cevaxin - 24 de Diciembre, Panama City
Cevaxin - Ave. México, Panama City
Cevaxin - Chorrera, Panama City
Collaborators (1)
Bill and Melinda Gates Foundation
OTHER
PT Bio Farma
INDUSTRY
Centers for Disease Control and Prevention
FED
Technical Resources International, Inc. (TRI)
UNKNOWN
Centro de Vacunación e Investigación (Cevaxin)
UNKNOWN
PATH
OTHER